4//SEC Filing
Inrig Jula 4
Accession 0001415889-25-003064
CIK 0001438533other
Filed
Feb 3, 7:00 PM ET
Accepted
Feb 4, 8:30 PM ET
Size
11.3 KB
Accession
0001415889-25-003064
Insider Transaction Report
Form 4
Inrig Jula
CHIEF MEDICAL OFFICER
Transactions
- Award
Common Stock
2025-01-31+30,000→ 89,443 total - Sale
Common Stock
2025-02-03$20.12/sh−4,207$84,645→ 85,236 total - Award
Employee stock option (right to buy)
2025-01-31+100,000→ 100,000 totalExercise: $20.46Exp: 2035-01-31→ Common Stock (100,000 underlying) - Sale
Common Stock
2025-02-04$20.11/sh−1,066$21,437→ 84,170 total
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.
- [F2]Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
- [F3]This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.
- [F4]One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.
Documents
Issuer
Travere Therapeutics, Inc.
CIK 0001438533
Entity typeother
Related Parties
1- filerCIK 0001902368
Filing Metadata
- Form type
- 4
- Filed
- Feb 3, 7:00 PM ET
- Accepted
- Feb 4, 8:30 PM ET
- Size
- 11.3 KB